- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 07.08. | COGNITION THERAPEUTICS INC - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| COGNITION THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 06.08. | Cognition Therapeutics, Inc.: Cognition Therapeutics Reports Financial Results for the Second Quarter 2026 and Provides Business Update | 131 | GlobeNewswire (Europe) | PURCHASE, N.Y., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage company developing product candidates that treat neurodegenerative disorders (the "Company"... ► Artikel lesen | |
| 06.08. | COGNITION THERAPEUTICS INC - 8-K, Current Report | 1 | SEC Filings | ||
| 13.07. | Cognition Therapeutics, Inc.: Cognition Therapeutics Participating in Fireside Chat at B. Riley Securities' Mind, Muscle & Vision Summit | 1 | GlobeNewswire (USA) | ||
| 01.07. | H.C. Wainwright reiterates Cognition Therapeutics stock rating on FDA alignment | 2 | Investing.com | ||
| 24.06. | Cognition Therapeutics, Inc.: Cognition Therapeutics Aligns on Key Aspects of Pivotal Study for Zervimesine (CT1812) in DLB Psychosis Following Receipt of FDA Meeting Minutes | 481 | GlobeNewswire (Europe) | - Zervimesine Would be the First Long-term, Durable Treatment Option with an Impact on Underlying Disease -- Company Developing NPI as a Measure of DLB Psychosis - PURCHASE, N.Y., June 24, 2026 (GLOBE... ► Artikel lesen | |
| 22.06. | H.C. Wainwright reiterates Cognition Therapeutics stock rating on patent news | 1 | Investing.com | ||
| 18.06. | COGNITION THERAPEUTICS INC - 8-K, Current Report | 3 | SEC Filings | ||
| 16.06. | Cognition Therapeutics, Inc.: Cognition Therapeutics Announces New Composition of Matter Patent, Extending Patent Protection for Lead Candidate, Zervimesine (CT1812) Through 2045 | 552 | GlobeNewswire (Europe) | PURCHASE, N.Y., June 16, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the "Company" or "Cognition") (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative... ► Artikel lesen | |
| 04.06. | COGNITION THERAPEUTICS INC - 8-K, Current Report | 1 | SEC Filings | ||
| 21.05. | Cognition Therapeutics, Inc.: Cognition Therapeutics Completes Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies with Psychosis | 444 | GlobeNewswire (Europe) | - Positive Discussion on Path Forward for Registrational Program - PURCHASE, N.Y., May 21, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical-stage... ► Artikel lesen | |
| 21.05. | COGNITION THERAPEUTICS INC - 8-K, Current Report | 4 | SEC Filings | ||
| 14.05. | Cognition Therapeutics receives donation to extend DLB program | 2 | Investing.com | ||
| 14.05. | Cognition Therapeutics, Inc.: Cognition Therapeutics Receives Second Philanthropic Donation to Extend Ongoing Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies | 1 | GlobeNewswire (USA) | ||
| 08.05. | COGNITION THERAPEUTICS INC - 10-Q, Quarterly Report | - | SEC Filings | ||
| 07.05. | Cognition Therapeutics GAAP EPS of -$0.05 beats by $0.02 | 5 | Seeking Alpha | ||
| 07.05. | Cognition Therapeutics, Inc.: Cognition Therapeutics Reports Financial Results for the First Quarter 2026 and Provides Business Update | 949 | GlobeNewswire (Europe) | Meeting with FDA Division of Psychiatry scheduled for May 2026 expected to informregistrational plans for zervimesine in DLB psychosis PURCHASE, N.Y., May 07, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics... ► Artikel lesen | |
| 07.05. | COGNITION THERAPEUTICS INC - 8-K, Current Report | - | SEC Filings | ||
| 31.03. | Cognition Therapeutics plant entscheidende Studie für Demenz-Wirkstoff | 3 | Investing.com Deutsch | ||
| 31.03. | Cognition Therapeutics plans late-stage trial for dementia drug | 1 | Investing.com |
1 2 Weiter >>
39 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 88,30 | +0,11 % | Kurssprünge und Kaufempfehlungen! Neues Kursziel bei Almonty! CTS Eventim und BioNTech melden sich zurück! | Was für ein Comeback! Im August ist die Aktie von Almonty um über 50 % explodiert! Dafür gibt es gute Gründe. Wolfram ist im Westen knapp und wird von der hochfahrenden Waffenproduktion in den USA dringend... ► Artikel lesen | |
| AMGEN | 371,90 | -0,35 % | Amgen: Tezspire Demonstrates Positive Phase 3 Results In Eosinophilic Esophagitis Across Both Co-primary And All Key Secondary Endpoints | Statistically Significant and Clinically Meaningful Disease and Symptom Improvements Compared to Placebo Maintained Through Week 52
Efficacy in a Third Epithelial-Driven... ► Artikel lesen | |
| NOVAVAX | 7,950 | -0,62 % | Novavax announces regulatory approvals for updated COVID shot | ||
| BIOGEN | 187,62 | -0,51 % | Veeva Systems: Veeva Vault CRM Selected by Biogen | Unified commercial platform to help speed the delivery of medicines to patientsPLEASANTON, Calif., Aug. 25, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Biogen has... ► Artikel lesen | |
| CLINUVEL | 5,318 | -0,26 % | Clinuvel Pharmaceuticals Ltd - 6-K, Report of foreign issuer | ||
| VIKING THERAPEUTICS | 27,850 | +0,36 % | Viking Therapeutics Has $502 Million in Cash and 1 Big Catalyst Left in 2026 -- Is That Enough? | ||
| INTELLIA THERAPEUTICS | 11,220 | +0,90 % | Cathie Wood's ARK buys Intellia stock, sells Roblox | ||
| TEMPUS AI | 55,25 | -0,04 % | Tempus AI (TEM) Jumped on Moderna's Melanoma Win. Did its $1.5B Personalis Acquisition Just Get Validated? | ||
| EDITAS MEDICINE | 2,750 | +0,73 % | Editas Medicine, Inc.: Editas Medicine Announces Second Quarter 2026 Results and Business Updates | EDIT-401 on track for CTN submission this month with data update in Q1 2027 Recently presented pre-clinical data demonstrating ~90% or greater mean reduction in multiple atherogenic lipoproteins,... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 8,450 | -0,35 % | BioCryst Pharmaceuticals, Inc.: BioCryst Announces Approval of ORLADEYO for Pediatric HAE Patients in Japan | - Expands availability of the first and only oral prophylactic therapy for patients with HAE ages 2 to RESEARCH TRIANGLE PARK, N.C., Aug. 25, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc.... ► Artikel lesen | |
| BIOMARIN PHARMACEUTICAL | 55,62 | -1,31 % | Piper Sandler reiterates Overweight on BioMarin stock at $88 target | ||
| NUREXONE BIOLOGIC | 0,349 | +4,18 % | Breaking News! NurExone Biologic plant großes Börsen-Upgrade! | ||
| EXELIXIS | 46,940 | -0,10 % | BMO initiates Exelixis stock at Market Perform, cites patent cliff | ||
| SAREPTA THERAPEUTICS | 18,240 | +1,33 % | Biotech-Player: Zelltherapie als Comeback-Story im Milliardenmarkt. Neue Ideen nach Corona von BioNTech, Qiagen und Biotech AG | ||
| CARDIOL THERAPEUTICS | 1,680 | +1,20 % | B.Riley stuft Cardiol Therapeutics mit Kauf ein: Kursziel impliziert über 400 % Potenzial |
Das Unternehmen COGNITION THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,010 (+0,98 %) liegt der Kurs bei 1,030 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu COGNITION THERAPEUTICS INC finden Sie auf Wallstreet Online.